Home>Topics>Companies>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

  1. All
  2. Commentary
  3. Headlines
  1. Dupilumab dermatitis trial underway

    Headlines

    Mon, 20 Oct 2014

    Regeneron Pharmaceuticals (NASDAQ: REGN ) and Sanofi (NYSE: SNY ) ( OTCQB:SNYNF ) initiate a Phase ..... blocks IL-4 and IL-13 signalling. It was created using Regeneron 's VelocImmune technology and is being co-developed with

  2. Positive DME Trial Results Trump PCSK9 Patent Lawsuit; Slightly Raising FVE

    Commentary

    Fri, 17 Oct 2014

    We are slightly raising Regeneron 's FVE to $365 per share (from ..... macular edema, which showed that Eylea demonstrated better efficacy and safety ..... patent infringement lawsuit against Regeneron /Sanofi’s PCSK9 drug, Alirocumab

  3. Amgen sues Sanofi and Regeneron

    Headlines

    Fri, 17 Oct 2014

    Sanofi (NYSE: SNY ) ( OTCQB:SNYNF ) and Regeneron Pharmaceuticals (NASDAQ: REGN ) alleging infringement on three of its patents ..... the manufacture, use and sale of Sanofi and Regeneron 's PCSK9 inhibitor alirocumab . Amgen recently

  4. Regeneron's Eylea works better vs Avastin and Lucentis in study

    Headlines

    Fri, 17 Oct 2014

    Oct 17 (Reuters) - Regeneron Pharmaceuticals Inc said on Friday that a head-to-head study showed that its Eylea treatment for diabetic macular edema created significantly greater improvement in visual acuity compared with Genentech's Avastin and Lucentis.

  5. Eylea beats Avastin and Lucentis in comparative study

    Headlines

    Fri, 17 Oct 2014

    Research Network (DRCR.net), Regeneron 's (NASDAQ: REGN ) Eylea (aflibercept) injection demonstrated ..... regimen was one fewer in the Eylea cohort compared to Avastin and ..... Lucentis and fewer patients in the Eylea group received criteria-based

  6. Portfolio Changes For The Third Quarter 2014

    Headlines

    Thu, 9 Oct 2014

    Allstate (NYSE: ALL ) CBS Corp. (NYSE: CBS ) Colgate-Palmolive (NYSE: CL ) Oracle (NYSE: ORCL ) Regeneron Pharmaceuticals (NASDAQ: REGN ) Schlumberger (NYSE: SLB ) Wells Fargo (NYSE: WFC ) Viacom (NASDAQ: VIAB ) Walgreen (NYSE

  7. FDA approves Eylea label expansion

    Headlines

    Mon, 6 Oct 2014

    The FDA approves Regeneron Pharmaceuticals ' ( REGN -0.7% ) Eylea (aflibercept) for the treatment of macular edema following retinal vein occlusion. It was previously cleared for the treatment

  8. Regeneron Pharmaceuticals Has A Bright Future Ahead

    Headlines

    Mon, 6 Oct 2014

    s remarks. Regeneron Pharmaceuticals Inc . (NASDAQ: REGN ) is an exception ..... FDA regarding Regeneron 's drugs EYLEA and Alirocumab. Regeneron is a fully integrated ..... Morningstar Regeneron 's Star Blockbuster EYLEA In the recently

  9. Dupilumab successful in Phase 2

    Headlines

    Tue, 30 Sep 2014

    Dupilumab , a humanized mAb being co-developed by Regeneron Pharmaceuticals (NASDAQ: REGN ) and Sanofi (NYSE: SNY ) ( OTCQB:SNYNF ), met all primary and secondary endpoints in a 60-patient Phase 2a proof-of

  10. Japanese health regulator approves Eylea label expansion

    Headlines

    Mon, 22 Sep 2014

    Welfare approves the use of Regeneron Pharmaceuticals ' (NASDAQ: REGN ) Eylea (aflibercept) injection ..... neovascularization (myopic CNV). Eylea is already approved for sale ..... vein occlusion (CRVO). Eylea is marketed in Japan by Bayer

« Prev12345Next »
Content Partners